Literature DB >> 7969078

Doxorubicin-induced DNA degradation in murine thymocytes.

G Zaleskis1, E Berleth, S Verstovsek, M J Ehrke, E Mihich.   

Abstract

Exposure of murine thymocytes to doxorubicin (Dox) (0.5-1.0 microM, 24 hr) triggered rapid DNA degradation, as indicated by the appearance of a major subdiploid population demonstrated by DNA flow cytometry. Electron microscopic comparison of samples with large subdiploid populations versus those with little or no such subset revealed significantly more cells with the characteristic features of apoptosis, the morphologically definable stage of programmed cell death. These features include unipolar condensed chromatin, zeiosis, and electron-dense cytoplasm. Dox-induced apoptosis occurred without prior S or G2/M phase arrest or cell size increase. The subset most susceptible to Dox-induced apoptosis in vitro and in vivo was CD3-CD4+CD8+. The same subset is affected by dexamethasone (Dex); as reported for Dex-induced apoptosis, actinomycin D and cycloheximide also blocked Dox-induced apoptosis. Thymocytes exposed to higher Dox concentrations (2-10 microM) did not have a subdiploid population. Although at 2-10 microM Dox significantly reduced cell numbers (probably as a result of necrosis), at least 5-10% of the population was viable at 24 hr. Thymocytes exposed to low concentrations of Dox (0.001-1.0 microM) plus Dex (0.1 microM) exhibited additive induction of apoptosis, whereas those exposed to high concentrations of Dox (2-10 microM) plus Dex were completely devoid of any evidence of apoptosis. These results indicate that the Dox-induced killing in thymocytes (mostly noncycling cells) occurs via different mechanisms depending upon the Dox concentration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969078

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Targeting lysophosphatidic acid receptor with Ki16425 impedes T cell lymphoma progression through apoptosis induction, glycolysis inhibition, and activation of antitumor immune response.

Authors:  Vishal Kumar Gupta; Ajay Kumar
Journal:  Apoptosis       Date:  2022-04-02       Impact factor: 4.677

2.  Effects of Chronic Endurance Exercise on Doxorubicin-Induced Thymic Damage.

Authors:  Colin J Quinn; Patrick D Burns; Noah M Gibson; Alex Bashore; Reid Hayward; David S Hydock
Journal:  Integr Cancer Ther       Date:  2015-11-20       Impact factor: 3.279

3.  Lipopolysaccharide augments the in vivo lethal action of doxorubicin against mice via hepatic damage.

Authors:  F Hassan; A Morikawa; S Islam; G Tumurkhuu; J Dagvadorj; N Koide; Y Naiki; I Mori; T Yoshida; T Yokochi
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

4.  B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage.

Authors:  Young-Bin Lim; Tae Jun Park; In Kyoung Lim
Journal:  J Biol Chem       Date:  2008-10-07       Impact factor: 5.157

5.  Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.

Authors:  Alex Bogason; Hasanuzzaman Bhuiyan; Michèle Masquelier; Christer Paul; Astrid Gruber; Sigurd Vitols
Journal:  Eur J Clin Pharmacol       Date:  2009-10-10       Impact factor: 2.953

6.  Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice.

Authors:  D Kim; A Monie; Y-C Tsai; L He; M-C Wang; C-F Hung; T-C Wu
Journal:  Gene Ther       Date:  2008-05-08       Impact factor: 5.250

7.  Binding of adriamycin to liposomes as a probe for membrane lateral organization.

Authors:  T Söderlund; A Jutila; P K Kinnunen
Journal:  Biophys J       Date:  1999-02       Impact factor: 4.033

8.  Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy.

Authors:  Jiejian Chen; Qiyao Yang; Minchen Liu; Mengting Lin; Tiantian Wang; Zhentao Zhang; Xincheng Zhong; Ningning Guo; Yiying Lu; Jing Xu; Changsheng Wang; Min Han; Qichun Wei
Journal:  Int J Nanomedicine       Date:  2019-10-08

9.  Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing.

Authors:  Yasmine F Ibrahim; Chi-Ming Wong; Ludmila Pavlickova; Lingling Liu; Lobsang Trasar; Geetanjali Bansal; Yuichiro J Suzuki
Journal:  J Am Heart Assoc       Date:  2014-02-26       Impact factor: 5.501

Review 10.  Chromatin as a target for the DNA-binding anticancer drugs.

Authors:  Parijat Majumder; Suman K Pradhan; Pukhrambam Grihanjali Devi; Sudipta Pal; Dipak Dasgupta
Journal:  Subcell Biochem       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.